Table 1 Baseline characteristics of enrolled patients
Variables | Group A | Group B | Group C | P value of overall comparison | P value of Group A versus Group B |
|---|---|---|---|---|---|
Pulmonary cGVHD (n = 15) | Non-pulmonary cGVHD (n = 256) | No cGVHD (n = 652) | |||
Mean age in years(range) | 42 (15–59) | 35 (14–67) | 38 (11–67) | 0.032 | 0.708 |
Male, n(%) | 10 (66.7%) | 157 (62.3%) | 379 (58.1%) | 0.567 | 0.679 |
Underlying disease, n(%) | Â | Â | Â | 0.038 | 1 |
 Leukemia or MDS | 15 (100%) | 239 (93.36%) | 564 (86.50%) |  |  |
 Lymphoma or myeloma | 0 | 6 (2.34%) | 26 (4%) |  |  |
 Aplastic anemia | 0 | 11 (4.3%) | 62 (9.5%) |  |  |
Donor type, n(%) | Â | Â | Â | 0.109 | 0.701 |
 Matched sibling | 5 (33.3) | 71 (27.7) | 138 (21.2) |  |  |
 Matched unrelated | 0 | 22 (8.6) | 76 (11.7) |  |  |
 Haplo-identical | 10 (66.7) | 163 (63.7) | 438 (67.2) |  |  |
Pre-HSCT pulmonary infection, n(%) | Â | Â | Â | 0.113 | 1 |
 Fungal infection | 1 (6.7) | 8 (3.13) | 14 (2.15) |  |  |
 Bacterial infection | 0 (0) | 3 (1.17) | 24 (3.68) |  |  |
 Other infection | 0 (0) | 2 (0.78) | 6 (0.92) |  |  |
Relapse after HSCT, n(%) | 2 (13.3) | 39 (15.2) | 105 (16.1) | 0.916 | Â |
Onset of aGVHD, n(%) | 5 (33.3) | 109 (42.6) | 220 (33.7) | 0.043 | 0.481 |
Median of aGVHD post-HSCT, months(range) | 0.73 (0.3–3.13) | 1.13 (0.3–3.2) | 0.9 (0–20.03) | 0.043 | 0.760 |
Median of cGVHD after HSCT,/months(range) | 9.1 (3.1–30.7) | 5.6 (0–53.5) | – | 0.023 | 0.023 |